Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

CANNANNEW REPORT

First Patient Expected to be Enrolled by Q2 of 2022 Data To Support Regulatory Filings in the United States BERWYN, Pa.–(BUSINESS WIRE)–#pharma—Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., a leading clinical trial services company, for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee. The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022. “Performing trials in Canada is an efficient and cost-effective way for Virpax to add robust data in support of the 505(b)(2) FDA approval pathway for Epoladerm™ . Through partners like Altasciences, we may strategically accelerate our optimized drug delivery therapeutic candidates through pre-clinical and clinical development,” commented Chairman & CEO Anthony P. Mack. About Epoladerm™ Virpax Pharmaceuticals is developing Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee. Our proprietary technology provides a convenient aerosol canister for application of the spray film to the knee. The resulting film is thinner than a standard liquid bandage, is visibly clear on the knee and is fast-drying. The spray formulation avoids the inconvenient and messy application of creams or gels to the knee. About Virpax Pharmaceuticals Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being…

Excerpt only …
READ MORE BELOW
Source : Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.